Distribution and patterns of industry-related payments to oncologists in 2014

Journal of the National Cancer Institute

Volumn 108, Issue 12, 2016, Pages

  Marshall, Deborah C ^a,b   Moy, Beverly ^c   Jackson, Madeleine E ^b   Mackey, Tim K ^a   Hattangadi Gluth, Jona A ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b University of California   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEDICAL EDUCATION; MEDICAL FEE; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RADIATION ONCOLOGIST; RADIATION ONCOLOGY; SURGICAL ONCOLOGY; UNITED STATES; ECONOMICS; INDUSTRY; ONCOLOGIST; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PROFESSIONAL PRACTICE; STATISTICS AND NUMERICAL DATA;

FEMALE; HUMANS; INDUSTRY; MALE; MEDICAL ONCOLOGY; ONCOLOGISTS; OWNERSHIP; PROFESSIONAL PRACTICE; PROFESSIONAL PRACTICE LOCATION; RADIATION ONCOLOGY; SURGICAL ONCOLOGY; UNITED STATES;

EID: 85015999329     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw163     Document Type: Article

References (51)

1. Moy B, Jagsi R, Gaynor RB, Ratain MJ. The impact of industry on oncology research and practice. Am Soc Clin Oncol Educ Book. 2015:130-137.
2. Conflict of interest in medical research, education, and practice. Lo, B and Field, MJ, eds. Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice. Washington, D.C.: National Academies Press; 2009.
3. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271(9):684-689.
4. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373-380.
5. Sah S, Loewenstein G. Nothing to declare: mandatory and voluntary disclosure leads advisors to avoid conflicts of interest. Psychol Sci. 2014;25(2): 575-584.
6. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338(2):101-106.
7. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454-465.
8. Steinbrook R. For sale: physicians' prescribing data. N Engl J Med. 2006;354(26): 2745-2747.
9. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290(2):252-255.
10. Smieliauskas F. Conflicts of Interest in Medical Technology Markets: Evidence from Orthopedic Surgery. Health Econ. 2016;25(6):723-739.
11. Patient Protection and Affordable Care Act, Public Law 111-148, USC HR 3590. 2010.
12. Tefferi A, Kantarjian H, Rajkumar SV, et al. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015;90(8):996-1000.
13. Mailankody S, Prasad V. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. JAMA Oncol. 2015;1(4):539-540.
14. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18(4):381-390.
15. Medicare, Medicaid, Children's Health Insurance Programs: transparency reports and reporting of physician ownership or investment interests. Centers for Medicare and Medicaid Services. 2013;Fed Regist (78):9457-9528.
16. Rosenthal ME, Mello MM. Sunlight as disinfectant-new rules on disclosure of industry payments to physicians. N Engl J Med 2013;368:2052-2054.
17. Moses H 3rd, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174-189.
18. Hampson LA, Joffe S, Fowler R, Verter J, Emanuel EJ. Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. J Clin Oncol. 2007;25(24):3609-3614.
19. Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer. 2007; 109(7):1239-1246.
20. Halperin EC, Hutchison P, Barrier RC Jr. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. Int J Radiat Oncol Biol Phys. 2004;59(5):1477-1483.
21. Jagsi R, Sheets N, Jankovic A, Motomura AR, Amarnath S, Ubel PA. Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. Cancer. 2009;115(12):2783-2791.
22. Moy B, Bradbury AR, Helft PR, Egleston BL, Sheikh-Salah M, Peppercorn J. Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. J Clin Oncol. 2013;31(21): 2678-2684.
23. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282(15):1453-1457.
24. National Plan and Provider Enumeration System (NPPES) Downloadable File. 2015; https://www.cms.gov/Regulations-and-Guidance/HIPAA-Administrati ve-Simplification/NationalProvIdentStand/DataDissemination.html. Accessed September 2015.
25. Claims-based price, age, sex and race-adjusted Medicare spending. 2012; http://www.dartmouthatlas.org/downloads/tables/pa-reimb-hrr-2012.xls. Accessed October 1, 2015.
26. Frequently asked questions, FAQ 8984. 2015; https://questions.cms.gov/faq. php?id=5005&faqId=8984. Accessed July 1, 2015.
27. Campbell EG, Rao SR, DesRoches CM, et al. Physician professionalism and changes in physician-industry relationships from 2004 to 2009. Arch Intern Med. 2010;170(20):1820-1826.
28. Chen C, Petterson S, Phillips R, Bazemore A, Mullan F. Spending patterns in region of residency training and subsequent expenditures for care provided by practicing physicians for Medicare beneficiaries. JAMA. 2014;312(22): 2385-2393.
29. Frequently asked questions, FAQ 8376. 2015; https://questions.cms.gov/faq. php?id=5005&faqId=8376. Accessed June 15, 2015.
30. McDonald JH. Handbook of Biological Statistics (3rd ed.). Baltimore, MD: Sparky House Publishing; 2014.
31. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461-494.
32. Ratain MJ. Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy. J Clin Oncol. 2014;32(22):2293-2295.
33. Schmidt C. Open Payments Program (aka the Sunshine Act) makes public debut. J Natl Cancer Inst. 2014;106(9):XXX-XXX.
34. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295(4):429-433.
35. Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008;5(1):e1.
36. Lockhart AC, Brose MS, Kim ES, et al. Physician and stakeholder perceptions of conflict of interest policies in oncology. J Clin Oncol. 2013;31(13):1677-1682.
37. Jairam V, Yu J. An examination of industry payments to radiation oncologists in 2014 using the CMS Open Payments database. International Jounral of Radiation Oncology, Biology, Physics. 2015;PII: S0360-3016(15)03314-3.
38. Chatterji AK, Fabrizio KR, Mitchell W, Schulman KA. Physician-industry cooperation in the medical device industry. Health Aff (Millwood). 2008;27(6): 1532-1543.
39. King S. Best selling cancer drugs-2014 and 2020. 2015; http://www.firstword pharma.com/node/1287604?tsid=17-axzz3bj8h6100. Accessed April 1, 2016.
40. Top 25 pharma companies by oncology sales. 2015; http://www.pmlive.com/top-pharma-list/oncology-revenues. Accessed April 1, 2016.
41. Tibau A, Bedard PL, Srikanthan A, et al. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. J Clin Oncol. 2015;33(1):100-106.
42. Jang S, Chae YK, Majhail NS. Financial conflicts of interest in economic analyses in oncology. Am J Clin Oncol. 2011;34(5):524-528.
43. Bariani GM, de Celis Ferrari AC, Hoff PM, Krzyzanowska MK, Riechelmann RP. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology. J Clin Oncol. 2013;31(18):2289-2295.
44. Hampson LA, Agrawal M, Joffe S, Gross CP, Verter J, Emanuel EJ. Patients' views on financial conflicts of interest in cancer research trials. N Engl J Med. 2006;355(22):2330-2337.
45. Rose SL, Sanghani RM, Schmidt C, Karafa MT, Kodish E, Chisolm GM. Gender Differences in Physicians' Financial Ties to Industry: A Study of National Disclosure Data. PLoS One. 2015;10(6):e0129197.
46. Hunt J, Garant J-P, Herman H, Munroe DJ. Working Paper Number 17888: Why Don't Women Patent? Natl Bureau Econ Res. 2012.
47. Kahler AI. Examining exclusion in woman-inventor patenting: a comparison of educational trends and patent data in the era of computer engineer barbie. J Gen Soc Policy Law. 2011;19(3):773-798.
48. Ding WW, Murray F, Stuart TE. Gender differences in patenting in the academic life sciences. Science. 2006;313:665.
49. Mackey TK, Liang BA. Physician payment disclosure under health care reform: will the sun shine? J AmBoard Fam Med. 2013;26(3):327-331.
50. Chressanthis G, Sfekas A, Khedkar P, Jain N, Poddar P. Determinants of pharmaceutical sales representative access limits to physicians. J Med Marketing. 2015;0(0):1-24.
51. Annual report to congress on the Open Payments program for fiscal year 2014. Centers for Medicare and Medicaid Services; 2015.